Lodonal / LDN

ldn package mockupLow Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications, is currently used as an immune modulator. Lodonal /LDN works by boosting levels of endorphins (peptides produced in the brain and adrenal glands). These natural peptides are also powerful modulators of the immune system. When you take Lodonal at bedtime, the typical protocol, it attaches to opioid receptors in the brain and immune cells temporarily blocking endorphins signals your body to increase endorphin production. The increased endorphin production helps orchestrate the activity of stem cells, macrophages, natural killer cells, T and B cells and other immune cells. Lodonal also prevents immune system over activity, the crux of autoimmune disorders, and blunts the release of inflammatory and neurotoxic chemicals in the brain. Dr. Bernard Bihari, a New York physician who previously studied immune responses primarily in HIV/AIDs patients, provided a 3-fold mechanistic approach to the use of LDN showing administration has the following effects on the immune system:



  • Increase in met-enkephalin (an endorphin produced in large amounts in the adrenal medulla) and β-endorphin in the blood stream;
  • Increase in the number and density of opiate receptors on the tumor cell membranes, thereby making them more responsive to the growth-inhibiting effects of the already present levels of endorphins, which in turn induces apoptosis in the cancer cells; and
  • Increase in absolute numbers of circulating cytotoxic T cells (CD8+/TH1) and natural killer cells (“NK cells”) as well as NK cell activity.

To date, LDN has been administered to patients across multiple indications to include autoimmune diseases and disorders, viral infections and cancer; under both clinical trials and off-label prescription use in the United States, UK and Canada.

LDN Patents
Mechanism Of Action
Lodonal (LDN): One of the RARE Drugs that Actually Helps Your Body to Heal Itself It is believed that Lodonal works on more then one receptor, in clinical trails Clinical evidence indicates overwhelmingly that opioids alter the development, differentiation, and function of immune cells, and that both innate and adaptive systems are affected. Bone marrow progenitor cells, macrophages, natural killer cells, immature thymocytes and T cells, and B cells are all involved. The brief blockade of opioid receptors between 2 a.m. and 4 a.m. that is caused by taking Lodonal at bedtime each night is believed to produce a prolonged up-regulation of vital elements of the immune system by causing an increase in endorphin and enkephalin production. Normal volunteers who have taken Lodonal in this fashion have been found to have much higher levels of beta-endorphins circulating in their blood in the following days. It is important to note that Lodonal both the TLR4 and opioid receptor mechanisms may play a role in mechanism of action, as the hypotheses are not mutually exclusive.
Clinical Trials